ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...
ICP-B02 binds to CD20 on the tumour cells and CD3 on the T cells, redirects and activates T cells to eradicate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...
BEIJING, January 20, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, together with their joint ...
The CD20xCD3 antibody, known as ICP-B02 or CM355, is currently undergoing a phase 1/2 trial in China for relapsed/refractory non-Hodgkin lymphoma (NHL). That trial has already produced ...
ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback